Novartis AG is hammering home its commitment to immune-dermatology by in-licensing MOR106, a novel antibody against IL-17C indicated in atopic dermatitis (AtD), from biotechs Galapagos NV and MorphoSys AG for €95m ($111m) upfront, which the companies will split 50/50.
The Swiss pharma's key new product, Cosentyx (secukinumab) an antibody targeting IL-17A for psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS), was the star of Novartis’s recent Q2 results, beating consensus and making $701m for the Swiss pharma
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?